REVIEW ARTICLE

Fundamental & Clinical Pharmacology SFPT · WILEY

Can cannabidiol have an analgesic effect?

Bartłomiej Kulesza[1] | **Marek Mazurek**[2] | **Jacek Kurzepa**[1]

[1]Chair and Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland

[2]Chair and Department of Neurosurgery and Paediatric Neurosurgery, Medical University of Lublin, Lublin, Poland

Correspondence
Bartłomiej Kulesza, Chair and Department of Medical Chemistry, Chodźki 4a (Collegium Pharmaceuticum), Lublin 20-093, Poland.
Email: kuleszabartek88@gmail.com; bartlomiej.kulesza@umlub.pl

Abstract

Background: Cannabis, more commonly known as marijuana or hemp, has been used for centuries to treat various conditions. Cannabis contains two main components cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD, unlike THC, is devoid of psychoactive effects and is well tolerated by the human body but has no direct effect on the receptors of the endocannabid system, despite the lack of action on the receptors of the endocannabid system.

Objectives and methods: We have prepared a literature review based on the latest available literature regarding the analgesic effects of CBD. CBD has a wide range of effects on the human body. In this study, we will present the potential mechanisms responsible for the analgesic effect of CBD. To the best of our knowledge, this is the first review to explore the analgesic mechanisms of CBD.

Results and conclusion: The analgesic effect of CBD is complex and still being researched. CBD models the perception of pain by acting on G protein-coupled receptors. Another group of receptors that CBD acts on are serotonergic receptors. The effect of CBD on an enzyme of potential importance in the production of inflammatory factors such as cyclooxygenases and lipoxygenases has also been confirmed. The presented potential mechanisms of CBD's analgesic effect are currently being extensively studied.

KEYWORDS
analgesic effect, analgesic mechanism, cannabidiol, cannabis, CBD

1 | INTRODUCTION

Cannabis, more commonly known as marijuana or hemp, has been used for centuries to treat various conditions. The Chinese are believed to have first used cannabis for medicinal purposes around 2900 BC. Cannabis root decoctions were used to treat arthritis and gout, among other things, as described by the Roman historian Pliny the Elder.[1,2] Currently, the use of marijuana for medicinal purposes is constantly increasing. The number of countries legalizing marijuana is increasing, and the Food and Drug Administration (FDA) has approved four cannabis-based drugs.[3,4] Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two phytocannabinols found in the highest concentrations in Cannabis sp.[5] The endocannabinoid system affects the broadly understood hemostasis of the body. Within the endocannabinoid system, CB1 and CB2 receptors are distinguished, which act via a G protein-coupled receptor (GPCR). THC is the main psychoactive component of cannabis with partial agonist activity at both cannabinoid receptors. Cannabidiol, unlike THC, is devoid of psychoactive effects and is well tolerated by the human body, but has no direct effect on the CB1 and CB2 receptors.[6–8] Observations to date have shown that CBD exerts a range of actions on the

Abbreviations: CBD, cannabidiol; COX, cyclooxygenase; dlPAG, dorsolateral periaqueductal gray; DRG, dorsal root ganglia; DRN, dorsal raphe nucleus; ECS, endocannabinoid system; FDA, Food and Drug Administration; GPCR, G Protein-Coupled Receptor; LOX, lipoxygenase; NAM, negative allosteric modulation; Nav, sodium channels; NSAID, nonsteroidal anti-inflammatory drug; THC, tetrahydrocannabinol; TRP, transient receptor potentials; TRPA, transient receptor potential of ankyrin; TRPM, transient receptor potential channels of melastatin; TRPV, transient receptor potential of vanilloid; VDAC, voltage-dependent anion channel.

human body, Table 1.[9–14] Such a comprehensive interaction is associated with the involvement of a number of signaling pathways; however, these have not yet been fully identified. Many hypotheses and potential relationships through which cannabinoids may act on the body are available in the literature. In this study, we will present the potential mechanisms responsible for the analgesic effect of CBD. To the best of our knowledge, this is the first review to explore the analgesic mechanisms of cannabidiol.

1.1 | Endocannabinoid system

Studies on the "endocannabinoid system (ECS)" were initiated by the identification of anandamide in the pig brain in 1992.[15] Endocannabinoids (eCB) are lipid mediators located in the brain and peripheral tissues. Endogenous cannabinoids are endogenous lipids that include amides, esters, and ethers of long chain polyunsaturated fatty acid. They mimic the action of tetrahydrocannabinol (THC) in different biological processes.[6,7] The best characterized endocannabinoids are anandamide (arachidonoyl ethanolamide) and 2-arachidonoyl glycerol (2-AG), their precursors are present in lipid membranes. In most cells, transport across the plasma membrane is associated with GPCRs or by depolarization. Anandamide is a partial agonist for CB1 and CB2 receptors. In contrast, 2-AG is a full agonist for both CB1 and CB2 receptors.[7,16,17] The endocannabinoid system affects the broadly understood hemostasis of the body. It is also important for pain perception. Distributions and functions of cannabinoid receptors are shown in Figure 1.[18]

1.2 | Cannabinoid receptors

The obvious mechanism of analgesic action would seem to be an effect on cannabinoid receptors. THC

TABLE 1 Action of CBD on the human body.

| CBD-action	Analgesic	Antidepressant	Immune-modulatory
	Antinausea	Neuroprotective	Antioxidant
	Anticancer	Anticonvulsant	Anti-inflammatory

FIGURE 1 Distributions and functions of cannabinoid receptors.

acts on cells primarily by binding to cannabionoid receptors CB1 and CB2 belonging to a class of cell membrane receptors in the GPCR.[19–21] CB1 receptors are characterized by a high prevalence in the presynaptic membranes of neurons within the spinal cord, midbrain, and basal ganglia.[22–28] CB2 receptors are primarily located within the peripheral nervous system and the immune system, Figure 1. Interestingly, they have also been shown to increase their expression in tissues following peripheral nerve damage.[26,27,29] This localization seems to explain the association of the receptors with the effects of cannabinoids on pain perception, thinking, memory, pleasure, coordination and movement. The mechanism of action of both types of receptors is to negatively regulate adenylate cyclase activity through their Gi/Goα, which results in a decrease in intracellular cAMP concentration.[30–32] cAMP interacts physiologically with a variety of ion channels, including the positively influenced inwardly rectifying potassium channels and calcium channels. Therefore, a decrease in the concentration of cAMP in the intracellular space causes the prolongation of presynaptic action potentials.[31,33,34]

However, in contrast to THC, observations by most authors show that CBD has relatively low activity toward cannabinoid receptors.[24,35–38] An exception is the results of Tham et al. where the authors demonstrated partial CBD agonism toward human CB2 receptors in HEK293A cells.[39] Interestingly, the study by Thomas et al. showed that much lower doses of CBD resulted in antagonistic effects induced by CB1 and CB2 agonists, probably by negative allosteric modulation (NAM) of the cannabinoid receptors.[37–39] This was

also confirmed by the observations of Pertwee et al. The authors showed a strongly antagonistic effect on CB1/CB2 receptor agonists. Furthermore, they suggested that, by affecting CB2 receptors, CBD influences the immune system by inhibiting the ability of immune cells to migrate.[40] This relationship was also apparent in the work of other authors.[25] Similarly, Laprairie et al. showed that CBD can act as a negative allosteric modulator of this receptor by inhibiting the effect of cannabinoid agonists.[41] Data on the effect of CBD on the signaling pathways of other cannabinoid ligands are also available in the literature.[42,43] The above results necessitate the search for other mechanisms explaining the analgesic effects of CBD Figure 2.

2 | MECHANISMS OF ANALGESIC ACTION

2.1 | GPCR

As previously mentioned, cannabinoid receptors belong to a large group of membrane receptors in eukaryotes which are GPCRs.[49] Data available in the literature show that, CBD can also interact with other receptors of this class. An example is the GPR55 receptor widely distributed within the brain.[50] It was characterized by John et al. who hypothesized that it was responsible for the blood pressure lowering properties of cannabinoids. However, this thesis was not supported by their findings.[51] In 2007, Ryberg et al. reported CBD activity on GPR55.[52] However, Lauckner et al. showed that this activation was not associated with an increase in


FIGURE 2 Receptors responsible for the analgesic effect of cannabidiol.[44–48]

intracellular calcium levels and activation of G(q), G(12), RhoA, actin, phospholipase C, and calcium release from IP(3)R-gated stores in contrast to the effect of THC.[53] A direct effect of CBD on rec GPR55 was not confirmed by Kapur et al. in their observations.[54] The exact role of GPR55 in the human body still remains a mystery, but its importance for its activation in inflammatory processes and pain modeling has been suggested.[55,56]

Other receptors in this group, which are GPR3, GPR6, and GPR12, also have an important affinity for CBD. As previous observations have shown, they are phylogenetically related to cannabinoid receptors.[44,45] The GPR3 receptor was the first of this family to be cloned from a mouse cDNA library in 1993.[57] Its expression is closely associated with the central nervous system including the cortex, cerebellum, hippocampus, amygdala, thalamus, hypothalamus, and pituitary.[58–60] The GPR6 receptor is widely distributed in the brain (primarily in the striatum, but also in the retrosplenial cortex, hippocampus, amygdala, and hypothalamus.[61,62] Both receptors have been the subject of observations by Loan et al. The authors showed that CBD significantly reduced β-arrestin 2 recruitment to both receptors suggesting a role as their inverse agonist.[63] They also analyzed another receptor, which is GPR12. Originally, its expression was associated with the pituitary gland, but in subsequent years it was also shown to be present in neurons located in the frontal cortex, piriform cortex, thalamus, hypothalamus, hippocampus, amygdala, and olfactory bulb.[64,65] In their work, Brown et al. showed that GPR12 is able to interact with CBD as an inverse agonist leading to inhibition of cAMP accumulation stimulated by the constitutively active GPR12.[66] The exact role of the aforementioned receptors has not yet been determined. Their role in the pathogenesis of neurodegenerative diseases is suspected. However, their role in pain modulation cannot be ruled out.[67]

2.2 | Serotonergic receptors

Another group of receptors associated with pain sensation are the serotonergic receptors. One of them is the 5HT1 receptor. In their work, Rock el. demonstrated that this type of receptor can also be affected by CBD. Its administration allowed for an antiemetic effect via indirect activation of the somatodendritic 5-HT1A autoreceptors in the dorsal raphe nucleus (DRN) in rats model.[46] Interesting observations on the interaction of serotonergic receptors with CBD were made by Campos et al. The authors analyzed the effects of CBD supply on 5-HT1A receptors present in the dorsolateral periaqueductal gray (dlPAG) of male Wistar rats—a midbrain structure responsible for, among other things, the sensation of anxiety. The rats were then subjected

to rat tests of anxiety and pain perception by the rodents. The tail-flick test showed that CBD induced an antinociceptive effect 15 min after administration. This was weaker than for morphine however, significant compared to the control group. The injections were even more significant in the effect on anxiety levels of the observed rats. CBD supply to dlPAG increased exploration of the open arms without changing the number of entries into the enclosed arms in the elevated plus maze (EPM) test. The anxiolytic effect of CBD was equally confirmed in the Vogel conflict test (VCT). Furthermore, the researchers were able to reverse the aforementioned effect by supplying WAY100635, which is a 5HT1A receptor antagonist, but not in the presence of AM251 which is an antagonist of CB1 receptors, suggesting an effect of CBD specifically on serotonergic receptors.[68]

The importance of cannabinoids in the modulation of serotonergic transmission has also been the subject of observations by Jesus et al. The authors tested the effect of CBD supply on mechanical allodynia in streptozotocin-induced diabetic (DBT) rats. Using the Von Frey test, CBD was shown to cause a significant antiallodynic effect mediated by 5HT1A receptors. This action could be reversed by the supply of WAY100135 (which is an antagonist of 5HT1A receptors), confirming the role of serotinergic transmission in this aspect. The supply of CB1, CB2 or glycine antagonists did not induce such effect.[69] In another study by De Gregorio et al. using in vivo single-unit extracellular recordings in rats, they analyzed the firing rate of 5-HT neurons in dorsal raphe nucleus. The administration of acute intravenous increasing doses of CBD was shown to reduce the firing rate of 5-HT neurons. Moreover, also in this case, this effect could be neutralized by the administration of WAY100635 and capsazepine (which is a TRPV1 receptor antagonist), but not AM251 (a CB1 receptor antagonist). This confirms the importance of 5HT1 and TRPV1 receptors in the modulatory effects of CBD on serotonergic transmission.[70] In a second stage of the experiment, the authors also tested the effects of repeated subcutaneous administration of CBD for 7 days in healthy rats. The effect was a significant increase in the mean firing rate of DRN 5-HT neurons probably as a result of desensitisation of 5-HT1A autoreceptors.[70] Furthermore, in a spared nerve injury rat model, repeated CBD injections for 24 days resulted in decreased mechanical allodynia, decreased 5-HT firing activity and increased anxiety-like behavior. In contrast, the effect of a 7-day supply of the compound was a decrease in mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity.[70] Again, the antiallodynic effect was reversed with 5-HT antagonists and, in a partial way, TRPV1 antagonists. Moreover, the antianxiolytic effect was only affected by WAY100635.[70] Conclusions from the observations of de Gregorio et al. showed that 5-HT1A receptors

significantly mediate the anxiolytic properties of CBD, but are only partly responsible for the analgesic effect.[70] In addition, the effect of capsazepine in reversing the antiallodynic effect of CBD indicates a dominant role for TRPV1 receptors in this aspect.[70]

2.3 | Opioid and dopamine receptors

The search for new receptors on which CBD interacts is also ongoing. Among others, CBD has been shown to interact with opioid receptors. Furthermore, computational analyses suggest the dopamine D3 receptor as a new potential target for this compound. However, further observations are needed to experimentally confirm this thesis.[71,72]

2.4 | Ionic channels

The result presented earlier shows that CBD can also exert analgesic effects through its action on ion channels. These include the transient receptor potential of vanilloid type 1 and 2 (TRPV1 and TRPV2) controlling the passage of Na+, K+, and Ca2+ across cell membranes. Transient receptor potentials (TRPs) belong to a larger group of cationic ion channels primarily present on the cell membranes of animal cells.[73] Their activation occurs primarily under the influence of capsaicin or heat above temperatures of $40°C$ (TRPV1) or $\sim50°C$ (TRPV2).[47,74] Both receptors are located within the central nervous system. TRPV1 are located, among others, in basal ganglia, hippocampus, cerebellum, diencephalon and DRG neurons while TRPV2 have been described in sensory neurons of the DRG, trigeminal ganglia, spinal cord and also within the cerebellum.[48,75–77] Another ion channel susceptible to cannabinoids is the transient receptor potential of ankyrin type 1 (TRPA1) which is often localized together with TRV1 in sensory neurons.[47,78–80] Activation of these receptors leads to depolarization of the cell membrane. In addition, TRPV1 and TRPA1 receptor-mediated functional desensitization, which manifests itself as a lack of receptor sensitivity to ligands after activation, is also observed.[5]

These mechanisms and the action on the aforementioned channels may be important in the antinociception effect. In their study, Maione et al. showed that CBD and CBC (cannabichromene) reduced electrical activity of ON and OFF neurons of the rostral ventromedial medulla in anaesthetized rat. This effect was dose-dependent. Moreover, it was reversible after treatment with selective antagonists of cannabinoid CB1, adenosine A1 and TRPA1 receptors, but not of TRPV1.[81] De Petrocellis et al. analyzed the effects of different phytocannabinoids on the activity of both vanilloid type 1 (TRPV1) and ankyrin type 1 (TRPA1) and the

menthol- and icilin-sensitive transient receptor potential channels of melastatin type 8 (TRPM8). CBD was shown to induce TRPA1-mediated Ca2 + elevation in HEK-293 cells. However, this action was weaker than with cannabichromene (CBC). Interestingly, they also observed an antagonistic effect of CBD on TRPM8 receptor activity.[82] In a subsequent study, the authors showed that CBD stimulate and desensitize human TRPV1 which was consistent with data previously available in the literature.[83–85] Furthermore, they showed that THC and CBD increase activity at TRPV2 channels.[83] An analogous agonistic effect of CBD on TRPV2 was also previously described by Qin et al.[86]

However, CBD can also affect the activity of other types of receptors. The result of the study by Ghovanloo et al. suggests that CBD can inhibit the activity of sodium channels (Nav) at therapeutically relevant concentrations. Interestingly, this effect was temperature dependent.[87] The observations of Ross et al. showed that CBD and THC can also inhibit low-voltage-activated T-type calcium Ca(V)3 channels located, among others, in neurons involved in nociceptive processing.[88] There are also data in the literature suggesting a modulatory effect of CBD on GABAA ionotropic receptors and voltage-dependent anion channel 1 (VDAC1).[78,89]

2.5 | Effects on transporters and enzymatic systems

However, the action of CBD on pain modulation is not necessarily through a direct receptor-mediated mechanism. Data available in the literature suggest an effect of endocannabinoids on the activity of transporters and enzymes involved in the metabolism of drugs used to treat pain which may potentiate their effects. Observations by Wheal et al. conducted on a rat model sought a mechanism for the anti-inflammatory and analgesic properties of CBD in preclinical models of diabetes. The authors showed that this action is mediated by an increase in the activity of both cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) which are major targets of non-steroidal anti-inflammatory drugs (NSAIDs).[90,91] In addition, CBD is an inhibitor of lipoxygenase (LOX), which is potentially involved in the production of inflammatory factors..[92] The anti-inflammatory effects of CBD have been repeatedly confirmed in preclinical observations.[93–97]

An inhibitory effect on the cytochrome P450 superfamily (CYPs) constituting major enzymes involved in many drug metabolisms, including NSAIDs commonly used in pain management, has also been described.[19,73] Studies in rats also demonstrated an inhibitory effect of CBD on fatty acid amide hydrolase (FAAH), but observations conducted on the human isoform of the enzyme did not confirm the physiological

significance of this relationship.[83,84] Results of analogous relevance were also obtained for mitochondrial complex I, II and IV, as well as testosterone hydroxylase and acyl-CoA cholesterin acyltransferase (ACAT), which are enzymes involved in steroid metabolism.[98–100] Studies by Carrier et al. have also shown the importance of CBD in reducing adenosine uptake suggesting its immunosuppressive effect by increasing endogenous adenosine signalling.[101] Similar observations were also made by Mijangos-Moreno et al. Additionally, the authors suggested that this relationship may be crucial in the sleep promoting effects of CBD.[102]

CBD also affects the activity of intracellular transporters of endocannabinoids such as fatty acid binding proteins 1, 3, 5, and 7.[102–104] There are reports of modulation of the activity of transporters of multidrug resistance proteins (multidrug resistance-associated protein 1 (ABCC1), ATP-binding cassette super-family G member 2 (ABCG2) or P-glycoprotein). However, this occurred at high concentrations of the substance, suggesting a lack of physiological relevance of this phenomenon.[5]

3 | LIMITATIONS

The limitations of this review are mainly due to the limitations of the available studies in the literature. Most of the available research in the literature has focused on cannabidiol and tetrahydrocannabinol. The premise of this study was to present the potential analgesic mechanisms of CBD itself. To the best of our knowledge, we have presented all the potential analgesic mechanisms of cannabidiol that have been studied. However, the presented mechanisms require confirmation in further studies.

4 | CONCLUSIONS

The analgesic effect of CBD is complex and still being researched. Unlike THC, CBD does not affect CB1 and CB2 receptors, but it can affect other cannabinoid receptors such as GPR55. Other GPCRs that can participate in pain modeling under the influence of CBD are GPR3, GPR6 and GPR12. The serotonergic receptors are another group of pain receptors.

The analgesic effect of CBD through the 5HT1A receptors has been demonstrated. 5HT1A receptors, along with TRPV1 receptors, participate in the modulating effect of CBD on serotonergic transmission. CBD also affects transient receptor potentials such as TRPV1 and TRPV2 and Ankyrin Type 1 Receptor Transient Potential (TRPA1). In addition, CBD may inhibit the activity of sodium channels (Nav) and inhibit low-voltage-activated T-type calcium Ca(V)3 channels

involved in nociceptive processing. However, the effects of CBD on pain modulation are not necessarily only through a direct receptor-mediated mechanism. The effect of CBD on an enzyme of potential importance in the production of inflammatory factors such as cyclooxygenases and lipoxygenases has been confirmed. An inhibitory effect on the cytochrome P450 superfamily, which are the main enzymes involved in the metabolism of many drugs, including NSAIDs, has also been described. The presented potential mechanisms of CBD's analgesic effect are currently being extensively studied.

AUTHOR CONTRIBUTIONS
Research concept and design: Bartłomiej Kulesza and Jacek Kurzepa. *Collection and/or assembly of data*: Bartłomiej Kulesza and Marek Mazurek. *Data analysis and interpretation*: Marek Mazurek. *Writing the article*: Bartłomiej Kulesza and Marek Mazurek. *Critical revision of the article*: Bartłomiej Kulesza and Jacek Kurzepa. *Final approval of the article*: Bartłomiej Kulesza, Marek Mazurek, and Jacek Kurzepa. All authors reviewed the results and approved the final version of the manuscript.

CONFLICT OF INTEREST STATEMENT
The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or nonfinancial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

ORCID
Bartłomiej Kulesza https://orcid.org/0000-0002-9973-9571

REFERENCES
1. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. *Chem Biodivers*. 2007;4(8):1614-1648. doi:10.1002/cbdv.200790144
2. Ryz NR, Remillard DJ, Russo EB. Cannabis roots: a traditional therapy with future potential for treating inflammation and pain. *Cannabis Cannabinoid Res*. 2017;2(1):210-216. doi:10.1089/can.2017.0028
3. Bridgeman MB, Abazia DT. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. *Pharm Therapeut*. 2017;42(3):180-188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312634/
4. Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: therapeutic use in clinical practice. *Int J Mol Sci*. 2022;23(6):3344. doi:10.3390/ijms23063344
5. Amin MR, Ali DW. Pharmacology of medical cannabis. *Adv Exp Med Biol*. 2019;1162:151-165. doi:10.1007/978-3-030-21737-2_8

6. Battista N, Di Tommaso M, Bari M, Maccarrone M. The endo-cannabinoid system: an overview. *Front Behav Neurosci*. 2012; 6:9. doi:10.3389/fnbeh.2012.00009

7. Lu HC, Mackie K. An Introduction to the endogenous cannabi-noid system. *Biol Psychiatry*. 2016;79(7):516-525. doi:10.1016/j.biopsych.2015.07.028

8. Rudisill TM, Innes, K(K), Wen, S, Haggerty, T, Smith, GS. The effects of cannabidiol on subjective states, cognition, and psy-chomotor function in healthy adults: a randomized clinical trial. *Fundam Clin Pharmacol*. 2023;37(3):663-672. doi:10.1111/fcp.12868

9. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treat-ment of psychosis in Parkinson's disease. *J Psychopharmacol*. 2009;23(8):979-983. doi:10.1177/0269881108096519

10. Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabi-noid and NMDA glutamate receptor systems in humans: prelimi-nary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35(1):198-202. doi:10.1016/j.pnpbp.2010.11.002

11. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter random-ized controlled trial. *Am J Psychiatry*. 2018;175(3):225-231. doi:10.1176/appi.ajp.2017.17030325

12. White CM. A review of human studies assessing cannabidiol's (CBD) therapeutic actions and potential. *J Clin Pharmacol*. 2019;59(7):923-934. doi:10.1002/jcph.1387

13. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain*. 2019;160(4):860-869. doi:10.1097/j.pain.0000000000001464

14. Ko GD, Bober SL, Mindra S, Moreau JM. Medical cannabis—the Canadian perspective. *J Pain Res*. 2016;9:735-744. doi:10.2147/JPR.S98182

15. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Sci-ence*. 1992;258(5090):1946-1949. doi:10.1126/science.1470919

16. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by ananda-mide. *Mol Pharmacol*. 2000;57(5):1045-1050. https://molpharm.aspetjournals.org/content/57/5/1045.long

17. Luk T, Jin W, Zvonok A, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. *Br J Pharmacol*. 2004;142(3):495-500. doi:10.1038/sj.bjp.0705792

18. Sarzi-Puttini P, Ablin J, Trabelsi A, Fitzcharles MA, Marotto D, Häuser W. Cannabinoids in the treatment of rheumatic diseases: pros and cons. *Autoimmun Rev*. 2019;18(12):102409. doi:10.1016/j.autrev.2019.102409

19. Guengerich FP. Cytochrome p450 and chemical toxicology. *Chem Res Toxicol*. 2008;21(1):70-83. doi:10.1021/tx700079z

20. Howlett AC. The cannabinoid receptors. *Prostaglandins Other Lipid Mediat*. 2002;68-69:619-631. doi:10.1016/s0090-6980(02)00060-6

21. Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A. Targeting the endocannabinoid sys-tem: future therapeutic strategies. *Drug Discov Today*. 2017; 22(1):105-110. doi:10.1016/j.drudis.2016.08.005

22. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y. Endocan-nabinoid signaling and synaptic function. *Neuron*. 2012;76(1): 70-81. doi:10.1016/j.neuron.2012.09.020

23. Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM. The neuronal distribution of cannabinoid receptor type 1 in the tri-geminal ganglion of the rat. *Neuroscience*. 2003;120(1):155-162. doi:10.1016/s0306-4522(03)00333-6

24. Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG. 6″-Azidohex-2″-yne-cannabidiol: a potential neu-tral, competitive cannabinoid CB1 receptor antagonist. *Eur J Pharmacol*. 2004;487(1–3):213-221. doi:10.1016/j.ejphar.2004.01.023

25. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the man-agement of acute and chronic pain episodes. *Curr Neurophar-macol*. 2006;4(3):239-257. doi:10.2174/157015906778019527

26. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol Rev*. 2002;54(2):161-202. doi:10.1124/pr.54.2.161

27. Jordan CJ, Xi ZX. Progress in brain cannabinoid CB2 receptor research: from genes to behavior. *Neurosci Biobehav Rev*. 2019;98:208-220. doi:10.1016/j.neubiorev.2018.12.026

28. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A*. 1990;87(5):1932-1936. doi:10.1073/pnas.87.5.1932

29. Guindon J, Hohmann AG. The endocannabinoid system and pain. *CNS Neurol Disord Drug Targets*. 2009;8(6):403-421. doi:10.2174/187152709789824660

30. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, canna-bidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol*. 2008; 153(2):199-215. doi:10.1038/sj.bjp.0707442

31. Demuth DG, Molleman A. Cannabinoid signalling. *Life Sci*. 2006;78(6):549-563. doi:10.1016/j.lfs.2005.05.055

32. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. *J Pharmacol Exp Ther*. 2005;315(2):828-838. doi:10.1124/jpet.105.089474

33. Rhee MH, Vogel Z, Barg J, et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. *J Med Chem*. 1997;40(20):3228-3233. doi:10.1021/jm970126f

34. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Can-nabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. *J Neurochem*. 1998;71(4):1525-1534. doi:10.1046/j.1471-4159.1998.71041525.x

35. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. *J Pharmacol Exp Ther*. 1998;285(1):285-292. https://jpet.aspetjournals.org/content/285/1/285.long

36. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral can-nabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther*. 1996;278(3): 989-999. https://jpet.aspetjournals.org/content/278/3/989.long

37. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol*. 2007;150(5):613-623. doi:10.1038/sj.bjp.0707133

38. Martínez-Pinilla E, Varani K, Reyes-Resina I, et al. Binding and signaling studies disclose a potential allosteric site for cannabi-diol in cannabinoid CB2 receptors. *Front Pharmacol*. 2017;8: 744. Published 2017 Oct 23. doi:10.3389/fphar.2017.00744

39. Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacol-ogy of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. *Br J Pharmacol*. 2019; 176(10):1455-1469. doi:10.1111/bph.14440

40. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. *Neurochem Res*. 2005;30(8): 1037-1043. doi:10.1007/s11064-005-6978-1

41. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Can-nabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol*. 2015;172(20):4790-4805. doi:10.1111/bph.13250

42. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease. *Mol Pharmacol*. 2016;89(3):364-375. doi:10.1124/mol.115.101980

43. Navarro G, Reyes-Resina I, Rivas-Santisteban R, et al. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes. *Biochem Pharmacol*. 2018;157:148-158. doi:10.1016/j.bcp.2018.08.046

44. Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands. *J Cell Biochem*. 2004; 92(5):923-936. doi:10.1002/jcb.20092

45. Morales P, Hurst DP, Reggio PH. Methods for the development of in silico GPCR models. *Methods Enzymol*. 2017;593:405-448. doi:10.1016/bs.mie.2017.05.005

46. Rock EM, Bolognini D, Limebeer CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT (1A) somatodendritic autoreceptors in the dorsal raphe nucleus. *Br J Pharmacol*. 2012;165(8):2620-2634. doi:10.1111/j.1476-5381.2011.01621.x

47. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature*. 1999;400(6743):452-457. doi:10.1038/22761

48. Caterina MJ, Julius D. Sense and specificity: a molecular identity for nociceptors. *Curr Opin Neurobiol*. 1999;9(5):525-530. doi:10.1016/S0959-4388(99)00009-4

49. Foord SM, Bonner TI, Neubig RR, et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacol Rev*. 2005;57(2):279-288. doi:10.1124/pr.57.2.5

50. Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and pain: a clinical review. *Cannabis Cannabinoid Res*. 2017;2(1):96-104. doi:10.1089/can.2017.0017

51. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. *Br J Pharmacol*. 2007;152(5):825-831. doi:10.1038/sj.bjp.0707419

52. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *Jama*. 2006;296(13):1633-1644. doi:10.1001/jama.296.13.jrv60011

53. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. *Circ Cardiovasc Qual Outcomes*. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689

54. Ballantyne JC. Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions. *Anesth Analg*. 2017;125(5):1769-1778. doi:10.1213/ANE.0000000000002500

55. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. *Pain*. 2008; 139(1):225-236. doi:10.1016/j.pain.2008.04.006

56. Kress M, Kuner R. Mode of action of cannabinoids on nociceptive nerve endings. *Exp Brain Res*. 2009;196(1):79-88. doi:10.1007/s00221-009-1762-0

57. Saeki Y, Ueno S, Mizuno R, et al. Molecular cloning of a novel putative G protein-coupled receptor (GPCR21) which is expressed predominantly in mouse central nervous system. *FEBS Lett*. 1993;336(2):317-322. doi:10.1016/0014-5793(93)80828-i

58. Hinckley M, Vaccari S, Horner K, Chen R, Conti M. The G-protein-coupled receptors GPR3 and GPR12 are involved in cAMP signaling and maintenance of meiotic arrest in rodent oocytes. *Dev Biol*. 2005;287(2):249-261. doi:10.1016/j.ydbio.2005.08.019

59. Iismaa TP, Kiefer J, Liu ML, Baker E, Sutherland GR, Shine J. Isolation and chromosomal localization of a novel human G-protein-coupled receptor (GPR3) expressed predominantly in the central nervous system. *Genomics*. 1994;24(2):391-394. doi:10.1006/geno.1994.1635

60. Zhang B, Ding J, Li Y, et al. The porcine Gpr3 gene: molecular cloning, characterization and expression level in tissues and cumulus-oocyte complexes during in vitro maturation. *Mol Biol Rep*. 2012;39(5):5831-5839. doi:10.1007/s11033-011-1393-y

61. Song ZH, Young WS 3rd, Brownstein MJ, Bonner TI. Molecular cloning of a novel candidate G protein-coupled receptor from rat brain. *FEBS Lett*. 1994;351(3):375-379. doi:10.1016/0014-5793(94)00888-4

62. Heiber M, Docherty JM, Shah G, et al. Isolation of three novel human genes encoding G protein-coupled receptors. *DNA Cell Biol*. 1995;14(1):25-35. doi:10.1089/dna.1995.14.25

63. Laun AS, Song ZH. GPR3 and GPR6, novel molecular targets for cannabidiol. *Biochem Biophys Res Commun*. 2017;490(1): 17-21. doi:10.1016/j.bbrc.2017.05.165

64. Eidne KA, Zabavnik J, Peters T, Yoshida S, Anderson L, Taylor PL. Cloning, sequencing and tissue distribution of a candidate G protein-coupled receptor from rat pituitary gland. *FEBS Lett*. 1991;292(1–2):243-248. doi:10.1016/0014-5793(91)80876-5

65. Ignatov A, Lintzel J, Hermans-Borgmeyer I, et al. Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. *J Neurosci*. 2003;23(3):907-914. doi:10.1523/JNEUROSCI.23-03-00907.2003

66. Brown KJ, Laun AS, Song ZH. Cannabidiol, a novel inverse agonist for GPR12. *Biochem Biophys Res Commun*. 2017;493(1): 451-454. doi:10.1016/j.bbrc.2017.09.001

67. Laun AS, Shrader SH, Brown KJ, Song ZH. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. *Acta Pharmacol Sin*. 2019; 40(3):300-308. doi:10.1038/s41401-018-0031-9

68. Campos AC, Guimarães FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology (Berl)*. 2008;199(2):223-230. doi:10.1007/s00213-008-1168-x

69. Jesus CHA, Redivo DDB, Gasparin AT, et al. Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. *Brain Res*. 2019;1715:156-164. doi:10.1016/j.brainres.2019.03.014

70. De Gregorio D, McLaughlin RJ, Posa L, et al. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. *Pain*. 2019; 160(1):136-150. doi:10.1097/j.pain.0000000000001386

71. Kathmann M, Flau K, Redmer A, Tränkle C, Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. *Naunyn Schmiedebergs Arch Pharmacol*. 2006; 372(5):354-361. doi:10.1007/s00210-006-0033-x

72. Kim D, Cavanaugh EJ, Simkin D. Inhibition of transient receptor potential A1 channel by phosphatidylinositol-4,5-bisphosphate. *Am J Physiol Cell Physiol*. 2008;295(1):C92-C99. doi:10.1152/ajpcell.00023.2008

73. Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. *Int J Mol Sci*. 2020;21(22):8870. doi:10.3390/ijms21228870

74. Zheng J. Molecular mechanism of TRP channels. *Compr Physiol*. 2013;3(1):221-242. doi:10.1002/cphy.c120001

75. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type

1 receptors in the mouse brain. *Neuroscience*. 2006;139(4): 1405-1415. doi:10.1016/j.neuroscience.2006.02.074

76. Kowase T, Nakazato Y, Yoko-O H, Morikawa A, Kojima I. Immunohistochemical localization of growth factor-regulated channel (GRC) in human tissues. *Endocr J*. 2002;49(3):349-355. doi:10.1507/endocrj.49.349

77. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. *Neuroscience*. 2000;100(4):685-688. doi:10.1016/s0306-4522(00)00389-4

78. Diógenes MJ, Assaife-Lopes N, Pinto-Duarte A, Ribeiro JA, Sebastião AM. Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors. *Hippocampus*. 2007;17(7):577-585. doi:10.1002/hipo.20294

79. Diogenes A, Akopian AN, Hargreaves KM. NGF up-regulates TRPA1: implications for orofacial pain. *J Dent Res*. 2007;86(6): 550-555. doi:10.1177/154405910708600612

80. Story GM, Peier AM, Reeve AJ, et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. *Cell*. 2003;112(6):819-829. doi:10.1016/s0092-8674(03)00158-2

81. Maione S, Piscitelli F, Gatta L, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. *Br J Pharmacol*. 2011;162(3):584-596. doi:10.1111/j.1476-5381.2010.01063.x

82. De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. *J Pharmacol Exp Ther*. 2008;325(3):1007-1015. doi:10.1124/jpet.107.134809

83. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol*. 2011;163(7):1479-1494. doi:10.1111/j.1476-5381.2010.01166.x

84. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*. 2001;134(4):845-852. doi:10.1038/sj.bjp.0704327

85. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther*. 2006; 318(3):1375-1387. doi:10.1124/jpet.106.105247

86. Qin N, Neeper MP, Liu Y, Hutchinson TL, Lubin ML, Flores CM. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. *J Neurosci*. 2008;28(24):6231-6238. doi:10.1523/JNEUROSCI.0504-08.2008

87. Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. *J Biol Chem*. 2018;293(43):16546-16558. doi:10.1074/jbc.RA118.004929

88. Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. *J Biol Chem*. 2008;283(23):16124-16134. doi:10.1074/jbc.M707104200

89. McGilveray IJ. Pharmacokinetics of cannabinoids. *Pain Res Manag*. 2005;10(suppl a):15A-22A. doi:10.1155/2005/242516

90. Wheal AJ, Cipriano M, Fowler CJ, Randall MD, O'Sullivan SE. Cannabidiol improves vasorelaxation in Zucker diabetic fatty rats through cyclooxygenase activation. *J Pharmacol Exp Ther*. 2014;351(2):457-466. doi:10.1124/jpet.114.217125

91. Miranda HF, Noriega V, Sierralta F, Sotomayor-Zárate R, Prieto JC. Risperidone in analgesia induced by paracetamol and meloxicam in experimental pain. *Fundam Clin Pharmacol*. 2022; 36(3):494-500. doi:10.1111/fcp.12754

92. Takeda S, Usami N, Yamamoto I, Watanabe K. Cannabidiol-2′,6′-dimethyl ether, a cannabidiol derivative, is a highly potent and selective 15-lipoxygenase inhibitor. *Drug Metab Dispos*. 2009;37(8):1733-1737. doi:10.1124/dmd.109.026930

93. Thapa D, Cairns EA, Szczesniak AM, Toguri JT, Caldwell MD, Kelly MEM. The cannabinoids Δ8THC, CBD, and HU-308 act via distinct receptors to reduce corneal pain and inflammation. *Cannabis Cannabinoid Res*. 2018;3(1):11-20. doi:10.1089/can.2017.0041

94. Hammell DC, Zhang LP, Ma F, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. *Eur J Pain*. 2016;20(6):936-948. doi:10.1002/ejp.818

95. Kozela E, Lev N, Kaushansky N, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. *Br J Pharmacol*. 2011;163(7):1507-1519. doi:10.1111/j.1476-5381.2011.01379.x

96. Pan H, Mukhopadhyay P, Rajesh M, et al. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. *J Pharmacol Exp Ther*. 2009;328(3):708-714. doi:10.1124/jpet.108.147181

97. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. *Eur J Pharmacol*. 2007;556(1–3):75-83. doi:10.1016/j.ejphar.2006.11.006

98. Fišar Z, Singh N, Hroudová J. Cannabinoid-induced changes in respiration of brain mitochondria. *Toxicol Lett*. 2014;231(1):62-71. doi:10.1016/j.toxlet.2014.09.002

99. Cornicelli JA, Gilman SR, Krom BA, Kottke BA. Cannabinoids impair the formation of cholesteryl ester in cultured human cells. *Arteriosclerosis*. 1981;1(6):449-454. doi:10.1161/01.atv.1.6.449

100. Watanabe K, Motoya E, Matsuzawa N, et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. *Toxicology*. 2005;206(3):471-478. doi:10.1016/j.tox.2004.08.005

101. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. *Proc Natl Acad Sci U S A*. 2006; 103(20):7895-7900. doi:10.1073/pnas.0511232103

102. Mijangos-Moreno S, Poot-Aké A, Arankowsky-Sandoval G, Murillo-Rodríguez E. Intrahypothalamic injection of cannabidiol increases the extracellular levels of adenosine in nucleus accumbens in rats. *Neurosci Res*. 2014;84:60-63. doi:10.1016/j.neures.2014.04.006

103. Elmes MW, Kaczocha M, Berger WT, et al. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). *J Biol Chem*. 2015;290(14):8711-8721. doi:10.1074/jbc.M114.618447

104. Huang H, McIntosh AL, Martin GG, et al. FABP1: a novel hepatic endocannabinoid and cannabinoid binding protein. *Biochemistry*. 2016;55(37):5243-5255. doi:10.1021/acs.biochem.6b00446